Based on our findings, D2-ag in conjunction with clinical strategies aimed at reducing VEGF mRNA levels may provide a more powerful inhibitory effect on VEGF and improve efforts to prevent OHSS. The gene discussed is VEGFA; the disease is ovarian hyperstimulation syndrome.